Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus Ipilimumab in dMMR Sarcoma and Endometrial Carcinoma
NCT02982486Phase 2Unknown
- Sponsor
- Shamir Medical Center
- Start
- Dec 2017
- Primary completion
- Jun 2020
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and ipilimumab in sarcoma and endometrial carcinoma, sponsored by Shamir Medical Center. Primary endpoint: Response to therapy at 36 months. Status: unknown.
02
Drugs
nivolumabipilimumab
03
Conditions
sarcomaendometrial carcinoma
Beyond the preview
Go deeper on NCT02982486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02982486.